DUBLIN – Aprea AB raised €46 million (US$50.7 million) in a series B round that will fund a phase IIb trial in ovarian cancer of its first-in-class p53 reactivator APR-246, as well as a series of exploratory trials in several other oncology indications in which p53 mutations are implicated. The compound works by stabilizing the conformation of p53 proteins with point mutations in the DNA binding domain and has already generated promising clinical data as monotherapy and in combination with chemotherapy.